BIOTECHNOLOGY VALUE FUND L P 13D/13G Filings for Corvus Pharmaceuticals, Inc. (CRVS)

BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Corvus Pharmaceuticals, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		 Transaction
Date		 Type Company
Symbol		 Filed By
Symbol		 Shares Owned
% Owned		 Shares Vs. Prev Report View
2022-02-11
7:30 pm
Sale		 2021-12-31 13G Corvus Pharmaceuticals, Inc.
CRVS		 BIOTECHNOLOGY VALUE FUND L P 1,370,947
3.000%		 -1,527,850decrease
(-52.71%)		 Filing
2021-02-12
4:09 pm
Sale		 2020-12-31 13G Corvus Pharmaceuticals, Inc.
CRVS		 BIOTECHNOLOGY VALUE FUND L P 2,898,797
9.990%		 -22,380decrease
(-0.77%)		 Filing